ERα

ERα (estrogen receptor alpha, ESR1) is a ligand-activated nuclear receptor and transcription factor that mediates estrogen-dependent gene regulation across reproductive, metabolic, skeletal, cardiovascular, and neural tissues^[1][2]. Upon estrogen binding, ERα regulates transcriptional programs controlling cellular proliferation, differentiation, development, and tissue homeostasis, thereby linking hormonal signaling to broad physiological responses^[1][3]. Mechanistically, ERα functions through both nuclear transcriptional regulation and membrane-initiated signaling pathways, enabling coordinated genomic and non-genomic responses to estrogen stimulation^[4]. Dysregulated ERα signaling contributes to multiple human diseases, particularly hormone-dependent cancers, where ERα acts as a major driver of tumor growth and progression and serves as a clinically important therapeutic target^[1][5]. In experimental and disease models, altered ERα activity has also been associated with metabolic disorders, cardiovascular disease, inflammation, neurodegeneration, and osteoporosis, highlighting its central role in systemic estrogen signaling^[1][2]. Compared with the related isoform ERβ, ERα generally promotes proliferative transcriptional programs, whereas ERβ frequently counterbalances ERα activity through inhibitory or modulatory effects on ERα-mediated gene expression^[2][6]. This functional divergence is a key consideration when dissecting estrogen receptor biology and disease mechanisms^[2][6]. For experimental applications, selective estrogen receptor modulators and ERα-targeting antagonists, including tamoxifen, raloxifene, and fulvestrant, are widely used to investigate ERα-dependent pathways and to evaluate endocrine therapeutic responses in disease models^[2].